Clobazam for refractory focal epilepsy. A controlled trial

Area of Science:

• Neurology
• Pharmacology

Background:

• Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
• Refractory epilepsy, often defined as seizures uncontrolled by adequate antiepileptic drug (AED) therapy, presents a significant clinical challenge.
• Standard AEDs may not be effective for all patients, necessitating exploration of add-on therapies.

Purpose of the Study:

• To evaluate the efficacy and tolerability of clobazam as an add-on treatment for chronic complex partial seizures.
• To assess the impact of clobazam on seizure frequency in patients with refractory epilepsy.

Main Methods:

• A double-blind, add-on trial was conducted involving 20 patients with chronic complex partial seizures.
• Patients were receiving maximally tolerable dosages of standard antiepileptic drug therapy.
• The study assessed seizure reduction over a three-month treatment period.

Main Results:

• A reduction in seizure frequency was observed during the three months of clobazam treatment.
• Forty percent (8/20) of patients experienced a >75% seizure reduction, with 20% (4/20) achieving complete seizure control.
• Tolerance to clobazam's antiepileptic effect was noted in 56% of patients, and 40% experienced mild transient sedation.

Conclusions:

• Clobazam demonstrates efficacy as an add-on therapy for managing refractory focal epilepsy.
• Despite potential drawbacks like tolerance and sedation, clobazam can be a valuable option for individual patients with difficult-to-treat epilepsy.
• Further research may explore strategies to mitigate tolerance and side effects.